MCID: THR024
MIFTS: 57

Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Thrombosis

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 12 29 54 43 15 71
Thrombosis of Blood Vessel 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060903
MeSH 43 D013927
UMLS 71 C0040053 C2586211

Summaries for Thrombosis

Disease Ontology : 12 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary : Thrombosis, also known as thrombosis of blood vessel, is related to cavernous sinus thrombosis and portal vein thrombosis. An important gene associated with Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Alprostadil and Nicorandil have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Thrombosis (from Ancient Greek θρόμβωσις thrómbōsis "clotting”) is the formation of a blood clot inside... more...

Related Diseases for Thrombosis

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2035)
# Related Disease Score Top Affiliating Genes
1 cavernous sinus thrombosis 35.1 SERPINC1 F3 F2
2 portal vein thrombosis 34.9 SERPINE1 SERPINC1 PROC PLAT MTHFR JAK2
3 coronary thrombosis 34.8 VWF SERPINE1 SERPINC1 PLAT GP1BA F3
4 sagittal sinus thrombosis 34.8 SERPINC1 F5 F3 F2
5 intracranial thrombosis 34.8 VWF SERPINC1 PLAT MTHFR GP1BA F5
6 lateral sinus thrombosis 34.8 SERPINC1 MTHFR F3 F2
7 intracranial sinus thrombosis 34.7 SERPINC1 MTHFR F3 F2
8 cerebral sinovenous thrombosis 34.6 PROS1 MTHFR F5 F3 F2 APOH
9 carotid artery thrombosis 34.6 VWF SERPINE1 SERPINC1 PLAT GP1BA F3
10 thrombophilia due to thrombin defect 34.4 THBD SERPINE1 SERPINC1 PROC PLAT MTHFR
11 budd-chiari syndrome 34.2 SERPINC1 MTHFR JAK2 FGB F5 F3
12 heparin-induced thrombocytopenia 33.7 SERPINC1 F3
13 antithrombin iii deficiency 33.5 SERPIND1 SERPINC1 MTHFR JAK2 F5 F3
14 paroxysmal nocturnal hemoglobinuria 33.4 THBD SERPINC1 F2 CD55
15 antiphospholipid syndrome 33.4 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
16 thoracic outlet syndrome 33.4 SERPINC1 PLAT F2
17 post-thrombotic syndrome 33.4 SERPINE1 SERPINC1 PLAT F5 F3 F2
18 prothrombin-related thrombophilia 33.4 MTHFR F2
19 protein s deficiency 33.3 THBD SERPINE1 SERPINC1 PROS1 PROC MTHFR
20 polycythemia vera 33.3 VWF THBD JAK2 F5 F2
21 hepatic veno-occlusive disease 33.2 THBD SERPINE1 SERPINC1 PLAT F3
22 may-thurner syndrome 33.2 F5 APOH
23 protein c deficiency 33.2 THBD SERPINE1 SERPINC1 PROC MTHFR HRG
24 moyamoya disease 1 33.2 VWF SERPINC1 MTHFR F3 F2
25 dysfibrinogenemia, congenital 33.2 THBD SERPIND1 SERPINC1 PLAT FGB F5
26 essential thrombocythemia 33.2 VWF THBD SERPINE1 SERPINC1 MTHFR JAK2
27 thrombophilia due to activated protein c resistance 33.2 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
28 shwartzman phenomenon 33.1 SERPINA10 F3
29 chronic venous insufficiency 33.1 SERPINE1 PLAT F2
30 factor vii deficiency 33.1 SERPINC1 F9 F3 F2
31 buerger disease 33.1 SERPINE1 MTHFR F2 APOH
32 homocysteinemia 33.1 VWF THBD SERPINE1 SERPINC1 MTHFR F5
33 pulmonary embolism 33.1 VWF THBD SERPINE1 SERPINC1 PROS1 PROC
34 factor v deficiency 33.0 VWF F9 F5 F3 F2
35 factor xii deficiency 33.0 VWF SERPINC1 F9 F5 F3 APOH
36 afibrinogenemia, congenital 32.9 VWF SERPINE1 SERPINC1 PLAT FGB F5
37 vascular disease 32.8 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
38 cardiovascular system disease 32.8 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR
39 thrombophilia 32.8 VWF THBD SERPINE1 SERPIND1 SERPINC1 SERPINA10
40 systemic lupus erythematosus 32.8 VWF THBD SERPINE1 JAK2 F3 F2
41 plasminogen activator inhibitor-1 deficiency 32.5 SERPINE1 PLAT
42 portal hypertension 32.1 VWF JAK2 F3 F2
43 varicose veins 32.1 VWF THBD SERPINC1 PLAT MTHFR F5
44 stroke, ischemic 32.1 VWF THBD SERPINE1 SERPIND1 SERPINC1 PLAT
45 papilledema 31.8 SERPINC1 F3 F2 APOH
46 thrombocytosis 31.8 VWF SERPINC1 JAK2 F3 F2
47 intermediate coronary syndrome 31.8 VWF SERPINC1 PLAT F3
48 intracranial hypertension 31.8 SERPINE1 SERPINC1 MTHFR F9 F5 F3
49 atherosclerosis susceptibility 31.8 VWF THBD SERPINE1 PLAT MTHFR F3
50 thrombocytopenia 31.8 VWF THBD SERPINE1 SERPINC1 PLAT MTHFR

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis

Symptoms & Phenotypes for Thrombosis

GenomeRNAi Phenotypes related to Thrombosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.5 JAK2
2 Decreased viability GR00249-S 9.5 F5 SERPINA10 SERPINE1
3 Decreased viability GR00381-A-1 9.5 PLAT SERPINA10
4 Decreased viability GR00381-A-2 9.5 SERPINA10
5 Decreased viability GR00381-A-3 9.5 SERPINA10
6 Decreased viability GR00386-A-1 9.5 GP1BA MTHFR PROS1 SERPINA10
7 Decreased viability GR00402-S-2 9.5 FGB HRG SERPINA10

MGI Mouse Phenotypes related to Thrombosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 APOH CD55 F2 F3 F5 F9
2 cardiovascular system MP:0005385 10.35 F2 F3 F5 F9 FGB JAK2
3 hematopoietic system MP:0005397 10.28 CD55 F2 F3 F9 GP1BA JAK2
4 embryo MP:0005380 10.11 F2 F3 F5 F9 FGB JAK2
5 immune system MP:0005387 10.11 CD55 F2 F3 F9 JAK2 PLAT
6 mortality/aging MP:0010768 10.11 APOH CD55 F2 F3 F5 F9
7 integument MP:0010771 9.97 F2 F3 F5 JAK2 MTHFR PLAT
8 liver/biliary system MP:0005370 9.91 F5 F9 JAK2 MTHFR PROC PROS1
9 nervous system MP:0003631 9.7 F2 F3 F5 MTHFR PLAT PROC
10 respiratory system MP:0005388 9.17 F2 F3 JAK2 PLAT PROC SERPINE1

Drugs & Therapeutics for Thrombosis

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 824)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
2
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
3
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
4
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
5
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
6
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
7
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
8
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Edoxaban Approved Phase 4 480449-70-5
11
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
12
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
13
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
14
Nadroparin Approved, Investigational Phase 4
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Pancrelipase Approved, Investigational Phase 4 53608-75-6
17
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
18
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
19
Liraglutide Approved Phase 4 204656-20-2 44147092
20 Orange Approved Phase 4
21
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
22 Taurolidine Approved, Investigational Phase 4 19388-87-5
23
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
24
Glimepiride Approved Phase 4 93479-97-1 3476
25 Nutmeg Approved Phase 4
26
Fenofibrate Approved Phase 4 49562-28-9 3339
27
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
28
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
29
Drospirenone Approved Phase 4 67392-87-4 68873
30
Ezetimibe Approved Phase 4 163222-33-1 150311
31
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
32 fluindione Approved, Investigational Phase 4 957-56-2
33
Pravastatin Approved Phase 4 81093-37-0 54687
34
Ranibizumab Approved Phase 4 347396-82-1 459903
35
Phenindione Approved, Investigational Phase 4 83-12-5 4760
36
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
37
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
38
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
39
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
40
acetic acid Approved Phase 4 64-19-7 176
41
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
42
Gliclazide Approved Phase 4 21187-98-4 3475
43
Canagliflozin Approved Phase 4 842133-18-0
44
Betrixaban Approved, Investigational Phase 4 330942-05-7
45
Propranolol Approved, Investigational Phase 4 525-66-6 4946
46
Dronedarone Approved Phase 4 141625-93-6, 141626-36-0 154087
47
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
48
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
50
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253

Interventional clinical trials:

(show top 50) (show all 3229)
# Name Status NCT ID Phase Drugs
1 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
2 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
3 Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
4 Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
5 A Prospective Randomized Controlled Trial of Efficacy and Safety of Anticoagulant Therapy With Low Molecular Weight Heparin and Warfarin in Portal Vein Thrombosis of Liver Cirrhosis Unknown status NCT04173429 Phase 4 Low molecular weight heparin (LMWH), warfarin
6 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
7 Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
8 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
9 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
10 Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
11 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
12 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
13 RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib) Unknown status NCT03178656 Phase 4 Sorafenib
14 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
15 Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study Unknown status NCT01375855 Phase 4
16 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
17 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
18 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
19 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
20 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
21 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
22 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
23 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
24 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
25 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
26 Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal. Unknown status NCT01927029 Phase 4 Progesterone;Placebo
27 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
28 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
29 Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis Unknown status NCT02402491 Phase 4 12 months of P2Y12 receptor antagonist;24 months of P2Y12 receptor antagonist;Aspirin
30 Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
31 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
32 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
33 Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery Unknown status NCT01648712 Phase 4
34 Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
35 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
36 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
37 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
38 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
39 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
40 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
41 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
42 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Unknown status NCT00714545 Phase 4
43 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
44 TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent) Unknown status NCT01510509 Phase 4
45 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
46 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
47 A Randomized Study Aimed at Comparing Activated Partial Thromboplastin Time and Anti-Xa Activity and in Patients Requiring Unfractionated Heparin Infusion Unknown status NCT03426982 Phase 4 Unfractionated heparin;Unfractionated heparin
48 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
49 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
50 A Randomized Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus SirOlimus ELUting Stent With Non-Biodegradable Polymer in the Treatment of PatIents With de nOvo Coronary Artery LesioNs Unknown status NCT00825773 Phase 4

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline

Cochrane evidence based reviews: thrombosis

Genetic Tests for Thrombosis

Genetic tests related to Thrombosis:

# Genetic test Affiliating Genes
1 Thrombosis 29

Anatomical Context for Thrombosis

MalaCards organs/tissues related to Thrombosis:

40
Liver, Heart, Testes, Endothelial, Brain, Lung, Kidney

Publications for Thrombosis

Articles related to Thrombosis:

(show top 50) (show all 31284)
# Title Authors PMID Year
1
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 54 61
20353989 2010
2
[Relationship of von Willebrand factor gene single-nucleotide polymorphism with thrombosis diseases]. 54 61
20416208 2010
3
Emerging roles of fibronectin in thrombosis. 61 54
20116835 2010
4
Acute mesenteric and aortic thrombosis associated with antithrombin deficiency: a rare occurrence. 54 61
19932950 2010
5
Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein1 in thrombosis. 54 61
20206880 2010
6
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 54 61
20004006 2010
7
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. 61 54
19883911 2010
8
Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. 61 54
20087632 2010
9
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report. 61 54
20034941 2010
10
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. 54 61
19582452 2010
11
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. 61 54
19497612 2010
12
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. 54 61
20425393 2010
13
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. 61 54
19398123 2010
14
Thrombosis markers in hip versus knee arthroplasty: a pilot study. 61 54
20065366 2009
15
ABO blood groups and genetic risk factors for thrombosis in Croatian population. 61 54
20017223 2009
16
Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. 54 61
20218141 2009
17
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. 61 54
19840484 2009
18
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. 54 61
19214510 2009
19
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. 61 54
19195685 2009
20
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 54 61
19660606 2009
21
Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. 54 61
19421222 2009
22
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. 54 61
19481472 2009
23
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 54 61
19414836 2009
24
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. 54 61
19193675 2009
25
Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. 54 61
19192108 2009
26
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. 54 61
19117960 2009
27
The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. 61 54
19353312 2009
28
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. 54 61
19180123 2009
29
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis. 54 61
19249467 2009
30
Mitogen-activated protein kinases in hemostasis and thrombosis. 54 61
18826389 2008
31
Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. 61 54
18575842 2008
32
Acute left atrial thrombosis during anticoagulant therapy in a patient with antithrombin deficiency. 54 61
19014009 2008
33
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis. 54 61
18514072 2008
34
Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system. 54 61
18295937 2008
35
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. 54 61
18375790 2008
36
Heparin induced thrombocytopenia with thrombosis: a two step process? 54 61
18702877 2008
37
The paradoxical association between inherited factor VII deficiency and venous thrombosis. 54 61
18282149 2008
38
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 54 61
18616871 2008
39
Arterial thrombosis associated with factor V Leiden and methylenetetrahydrofolate reductase C677T mutation in childhood membranous glomerulonephritis. 61 54
18030499 2008
40
Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. 54 61
18208809 2008
41
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 54 61
18480584 2008
42
Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. 54 61
18045662 2008
43
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. 54 61
18590927 2008
44
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. 54 61
17261530 2007
45
Plasminogen activator inhibitor-1 in vascular thrombosis. 61 54
17896948 2007
46
Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. 54 61
17908667 2007
47
Late drug-eluting stent thrombosis and erythropoietin: cause and effect? 54 61
17446131 2007
48
Combined effects of thrombosis pathway gene variants predict cardiovascular events. 61 54
17677000 2007
49
Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients. 54 61
17804532 2007
50
Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. 54 61
17534796 2007

Variations for Thrombosis

Expression for Thrombosis

Search GEO for disease gene expression data for Thrombosis.

Pathways for Thrombosis

Pathways related to Thrombosis according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 THBD SERPINC1 PROS1 PROC FGB F9
2
Show member pathways
12.63 VWF THBD SERPINE1 SERPIND1 SERPINC1 PROS1
3
Show member pathways
12.2 VWF THBD SERPINE1 SERPIND1 SERPINC1 PROS1
4
Show member pathways
12.16 SERPINE1 PLAT MTHFR F2
5
Show member pathways
12.06 THBD PROS1 PROC F2
6 11.96 VWF THBD SERPINE1 SERPIND1 SERPINC1 PROS1
7 11.87 VWF GP1BA FGB F2
8
Show member pathways
11.79 PROS1 PROC F9 F2
9 11.73 THBD SERPINE1 JAK2 F3
10
Show member pathways
11.7 VWF GP1BA FGB F2
11 11.38 VWF FGB F2
12 10.8 PROS1 PROC F9 F2
13 10.66 VWF GP1BA
14 10.66 SERPINE1 PLAT HRG
15 10.54 VWF GP1BA

GO Terms for Thrombosis

Cellular components related to Thrombosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.31 THBD SERPINE1 SERPINC1 PROS1 JAK2 HRG
2 extracellular exosome GO:0070062 10.17 VWF SERPINE1 SERPIND1 SERPINC1 SERPINA10 PROS1
3 extracellular region GO:0005576 10.06 VWF SERPINE1 SERPIND1 SERPINC1 SERPINA10 PROS1
4 cell surface GO:0009986 10.01 THBD PLAT HRG GP1BA FGB F3
5 endoplasmic reticulum lumen GO:0005788 9.91 SERPIND1 SERPINC1 SERPINA10 PROC F9 F5
6 blood microparticle GO:0072562 9.83 SERPINC1 PROS1 HRG FGB F2
7 extracellular space GO:0005615 9.83 THBD SERPINE1 SERPIND1 SERPINC1 SERPINA10 PROS1
8 Golgi lumen GO:0005796 9.78 PROS1 PROC F9 F2
9 platelet alpha granule lumen GO:0031093 9.73 VWF SERPINE1 PROS1 HRG FGB F5
10 platelet alpha granule GO:0031091 9.63 VWF FGB F5
11 collagen-containing extracellular matrix GO:0062023 9.32 VWF SERPINE1 SERPINC1 PLAT HRG FGB

Biological processes related to Thrombosis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.98 VWF SERPINE1 PROS1 HRG FGB F5
2 cellular protein metabolic process GO:0044267 9.97 SERPIND1 SERPINC1 SERPINA10 PROC F5 F2
3 post-translational protein modification GO:0043687 9.96 SERPIND1 SERPINC1 SERPINA10 PROC F5
4 ER to Golgi vesicle-mediated transport GO:0006888 9.95 PROS1 PROC F9 F5 F2 CD55
5 negative regulation of endopeptidase activity GO:0010951 9.93 SERPINE1 SERPIND1 SERPINC1 SERPINA10 PROS1 HRG
6 platelet activation GO:0030168 9.91 VWF HRG GP1BA FGB F2
7 negative regulation of peptidase activity GO:0010466 9.85 SERPINE1 SERPIND1 SERPINC1 SERPINA10
8 blood coagulation, intrinsic pathway GO:0007597 9.8 VWF GP1BA F9 F2 APOH
9 hemostasis GO:0007599 9.8 VWF THBD SERPIND1 SERPINC1 SERPINA10 PROS1
10 regulation of complement activation GO:0030449 9.77 PROS1 F2 CD55
11 negative regulation of blood coagulation GO:0030195 9.77 THBD SERPINE1 PROS1 PROC APOH
12 regulation of blood coagulation GO:0030193 9.72 SERPINC1 HRG GP1BA F2 APOH
13 positive regulation of blood coagulation GO:0030194 9.71 SERPINE1 F2 APOH
14 plasminogen activation GO:0031639 9.7 PLAT FGB APOH
15 fibrinolysis GO:0042730 9.7 SERPINE1 PROS1 PLAT HRG GP1BA FGB
16 negative regulation of fibrinolysis GO:0051918 9.65 THBD SERPINE1 HRG F2 APOH
17 negative regulation of cell adhesion mediated by integrin GO:0033629 9.58 SERPINE1 HRG
18 cytolysis by host of symbiont cells GO:0051838 9.58 HRG F2
19 negative regulation of platelet activation GO:0010544 9.57 THBD F2
20 blood coagulation GO:0007596 9.53 VWF THBD SERPIND1 SERPINC1 SERPINA10 PROS1

Molecular functions related to Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type peptidase activity GO:0008236 9.73 PROC PLAT F9 F2
2 signaling receptor binding GO:0005102 9.73 SERPINE1